Literature DB >> 25180396

Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’.

Sebastian Dolff, Wayel H Abdulahad, Cees G M Kallenberg.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25180396      PMCID: PMC4060459          DOI: 10.1186/ar4576

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


× No keyword cloud information.

We read with great interest the article by Brkic and colleagues in a recent issue of Arthritis Research & Therapy[1]. In that study, the authors investigated the distribution of T helper (Th) subsets which produce IL-17A, IL-17 F, IL-21, and IL-22 in patients with systemic lupus erythematosus (SLE) in relation to their genetic IFN type I signature. Patients with an IFN type I-positive signature showed increased percentages of IL-17A- and IL-21-producing CCR6+ T cells. From these results, the authors conclude that IFN type I cells co-act with Th17 cytokines in the pathogenesis of SLE. Surprisingly, they excluded CD25+ T cells from their analysis. In a previous study, we showed that Th cells from SLE patients expressing CD25med and CD25high are also able to produce IFN-γ and IL-17A [2]. Therefore, it would be relevant to assess cytokine expression in CD4+CD25+ T cells from IFN type I-positive and IFN type I-negative SLE patients. Furthermore, it should be proven that the genetic signature is solely responsible for the increased IFN production by Th cells. In addition, their finding that CCR6+ T cells are capable of producing IL-21 indirectly confirms our previous observation that IL-17+ T cells are a main source of IL-21 in patients with SLE [3]. Possibly, IL-21 is orchestrating the Th1/Th17 axis. Finally, we agree that there might be a co-activity between IFN-I- and IL-17-producing cells as described by Brkic and colleagues. However, considering our findings that T cells with a regulatory phenotype are able to produce IFN-γ and IL-17A in patients with SLE, we suggest that primarily the plasticity of T cells is altered in patients with SLE [4].

Abbreviations

IFN: Interferon; IL: Interleukin; SLE: Systemic lupus erythematosus; Th: T helper.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors contributed to the interpretation of data. SD drafted the manuscript. All authors read and approved the final manuscript.
  4 in total

1.  Disturbed Th1, Th2, Th17 and T(reg) balance in patients with systemic lupus erythematosus.

Authors:  Sebastian Dolff; Marc Bijl; Minke G Huitema; Pieter C Limburg; Cees G M Kallenberg; Wayel H Abdulahad
Journal:  Clin Immunol       Date:  2011-08-16       Impact factor: 3.969

2.  Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells.

Authors:  Hans J P M Koenen; Ruben L Smeets; Paul M Vink; Esther van Rijssen; Annemieke M H Boots; Irma Joosten
Journal:  Blood       Date:  2008-07-10       Impact factor: 22.113

3.  Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus.

Authors:  Sebastian Dolff; Wayel H Abdulahad; Johanna Westra; Berber Doornbos-van der Meer; Pieter C Limburg; Cees G M Kallenberg; Marc Bijl
Journal:  Arthritis Res Ther       Date:  2011-09-29       Impact factor: 5.156

4.  T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?

Authors:  Zana Brkic; Odilia B J Corneth; Cornelia G van Helden-Meeuwsen; Radboud J E M Dolhain; Naomi I Maria; Sandra M J Paulissen; Nadine Davelaar; Jan Piet van Hamburg; Paul L van Daele; Virgil A Dalm; P Martin van Hagen; Johanna M W Hazes; Marjan A Versnel; Erik Lubberts
Journal:  Arthritis Res Ther       Date:  2014-03-06       Impact factor: 5.156

  4 in total
  1 in total

1.  Response to ‘T-helper 17 cell cytokines and interferon type I: partners in crime in systemic lupus erythematosus?’ – Authors’ reply.

Authors:  Zana Brkic; Odilia B J Corneth; Marjan A Versnel; Erik Lubberts
Journal:  Arthritis Res Ther       Date:  2014       Impact factor: 5.156

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.